ArticleFrontiers in immunology2025
Identification of locally advanced rectal cancer-related genes based on transcriptome and mendelian randomization analysis with biological validation.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer remains one of the leading causes of cancer-related mortality worldwide, with locally advanced rectal cancer (LARC) representing a particularly challenging clinical subset. Deciphering the molecular mechanisms of LARC is essential for the development of more effective and personalized therapeutic strategies. Methods: Gene expression profiles from the Gene Expression Omnibus (GEO) database were analyzed to identify differentially expressed genes (DEGs) in LARC. Mendelian randomization (MR) analysis was subsequently performed using publicly available eQTL data to assess potential causal relationships between these DEGs and LARC. External validation of DEGs was conducted using data from the Cancer Genome Atlas (TCGA). Enrichment analyses were further conducted to explore the biological significance. To characterize the immunological landscape of LARC, immune cell infiltration and scRNA-seq analyses were employed. Survival analysis was conducted to evaluate the prognostic relevance. Finally, functional assays were performed on selected gene to validate its roles in LARC pathogenesis Results: A total of 1, 113 upregulated and 1, 233 downregulated genes were identified in LARC. MR analysis, combined with external TCGA validation, revealed 9 significant co-expressed genes (CEGs) potentially involved in LARC pathogenesis. These CEGs were primarily enriched in pathways related to immune regulation, oxidative stress response, ERK1/ERK2 and JAK-STAT signaling, as well as cancer metabolism and therapeutic resistance. Immune infiltration and scRNA-seq analyses revealed notable alterations in the tumor microenvironment and distinct expression patterns of the CEGs. Notably, Conclusion: This study offers new insights into the molecular mechanisms underlying LARC pathogenesis and identifies potential therapeutic targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.